Pod Insights Finshots Daily Will pharma help Kodak survive? About this episode In today’s episode on 19th August 2025, we tell you if Kodak is on the verge of shutting down and whether its unlikely bet on pharma could keep the shutters open.
Transcript 0:00 Speaker 00 Hello folks, you're listening to Finshots Daily and in today's episode, we tell you if Kodak is on the verge of shutting down and whether its unlikely bet on pharma could keep the shutters open.
0:12 Speaker 00 Before we begin, here's a quick word from team Ditto. Life has a way of surprising us and not always in a good way. Sometimes it's a sudden illness or an unexpected hospital visit that can shake up everything. In India, families still pay about thirty-nine percent of medical expenses directly from their own pockets and just one hospital stake can wipe out years of savings. The easiest way to protect yourself is by getting a good health insurance plan. It's way cheaper than footing one huge bill. And if you're unaware where to start, book a free call with Ditto. No spam, just honest, jargon-free guidance. Trusted by over eight lakh people for their health and term insurance needs. The link is in the description. Now, back to the story. It's the summer of nineteen nineties.
0:55 Speaker 00 You're on a family vacation with a chunky Kodak camera in hand. You wind up the reel, press the button, hear that crisp shutter click and wait weeks before those photos show up in an album. Or the Kodak moments everyone spoke of. For decades, this was a ritual and Kodak wasn't just a brand but a synonym for photography itself. The numbers tell you that. In the nineteen seventies, Kodak sold over eighty-five percent of all the cameras and films in the US. And by the early two thousands, its Digital and Film Imaging Systems Division was pulling in around nine billion dollars in annual sales, making up a bulk of Kodak's thirteen billion dollar revenue. But inside that number was a split that hinted at the company's future.
1:39 Speaker 00 Nearly six billion dollars still came from traditional film and photo paper, while only two point seven billion dollars came from digital cameras. So, you could say that Kodak made a huge chunk of its money on film and processing, but not on cameras. And that made sense because the more pictures people took, the more film Kodak sold and that's where the fat margins at. The only problem, once smartphones put cameras in everyone's pocket and cloud storage replaced albums, there was no need for physical films or processing them. And so Kodak's profit machine started to shrink. Kodak's downfall was swift. It filed for bankruptcy in 2012 and by 2024, its revenue had shrunk to just $1 billion.
2:22 Speaker 00 The irony is Kodak once held thousands of patents that could have made it a strong player in digital cameras, but it clung too tightly to film and missed the smartphone wave. When bankruptcy hit, those patents were sold off to a consortium of tech giants like Apple and Google and the company that once defined memories was reduced to a niche player surviving on printing plates, workflow software and chemicals. All of which brings us to today. The company recently said in its filing that there's substantial doubt about whether it can continue as a going concern. And the reason is hard cold math. It owes $477 million in short-term loans, but it only has $155 million in cash.
3:04 Speaker 00 To cover this gap, Kodak is hoping a one-time pension plan reversion brings in about $300 million. If regulators approve it, that money would go straight to debt repayment. Now, the company insists that this doesn't mean it plans to cease operations, shut shop or file for bankruptcy. And the going concern warning, it says was simply a mandatory disclosure. But here's the real question. Even if the pension cash came through, how does Kodak service what's left of its debt and still find a way to grow? Strangely enough, the answer is pharmaceuticals. At first glance, it sounds absurd, I know. How does a 133-year-old camera company get into making drugs? But dig a little deeper and you'll see Kodak has always been a chemical company in disguise.
3:49 Speaker 00 Its very first innovation in 1880, the dry photographic plate, was really a chemical breakthrough. Before it was invented, photographers' only choice was to use wet plates which were fragile, messy and a hassle to carry around. In contrast, dry plates were portable and quick to use. But making them meant that the process wasn't about the glass and coatings alone, it needed chemical mixing and a controlled environment. And for years, Kodak was importing these chemicals from Germany. But World War I changed that. Germany cut off supply of key ingredients and that's when George Eastman, the company's founder, vowed that they would never depend on anyone else for their chemicals.
4:29 Speaker 00 So in 1920, he found Tennessee Eastman, their specialty chemical arm that quietly churned out polyesters, plastics and industrial solvents while the photo business hogged the limelight. And it eventually grew into Eastman Chemical, a Fortune 500 giant. And that chemical legacy is what Kodak is leaning on today. Making drugs is a complicated process and it starts with something called key starting materials or KSMs. These are the building blocks that go through many stages to eventually become active pharmaceutical ingredients or APIs. Simply put, without KSMs, there can't be medicines and Kodak has an advanced materials and chemicals. That is AMNC division with all kinds of KSMs
5:13 Speaker 00 used for electronics and of course healthcare. It produced solvents, specialty chemicals and unregulated healthcare inputs. During the pandemic in 2020, for instance, the US government even tried to hand Kodak a $7.65 million loan to make drug ingredients onshore. While the deal collapsed in controversy, it revealed how strategic Kodak's know-how could be. And right now, the AMNC division is small but vital for Kodak. It's the only segment that's driving some growth in the company. In Q2 2025, it pulled in $75 million or a third of Kodak's total revenue and about $8 million in operational profits. That's 11% profit margin and when analyzed,
5:56 Speaker 00 that could come to a $300 million business giving over $30 million in profits. It's not a film-era money but compared to Kodak's print division which brings in Seventy percent of sales yet loses money at the operating level. It looks like the only engine worth betting on. And that's exactly what Kodak is doing. In Rochester, it has built an FDA-approved plant that will first make a basic lab solution called phosphate-buffett saline. The plan is to move from this simple start to IV saline and eventually to more complex pharma KSMs. But will that be enough to save Kodak, you ask? Well, even if Kodak successfully adds fifty to hundred million dollars in new pharma revenues in the next couple of years,
6:37 Speaker 00 at a margin of, say, twelve or fifteen percent, that's only six to fifteen million dollars in incremental operating profit. Step out capital expenditure and working capital and you're left with maybe four to ten million dollars of extra cash a year. Useful, sure, but not enough to transform its finances. So maybe pharma isn't the cavalry. It's the operating story that convinces lenders that Kodak might have a future. And that narrative isn't baseless. Kodak's trends in process chemistry, coating science, and large-scale, high-quality production transfer neatly to pharmaceuticals. Its Eastman Business Park in Rochester is a unique asset. And US policy that favors domestic pharma production could give it a tailwind.
7:20 Speaker 00 If Kodak can lock in multi-year contracts, it gains the badly needed stability. That's what Fuji Film, Kodak's old rival, did. Faced with the same collapse of film, Fuji redeployed its chemical expertise into healthcare, specialty chemicals, specialty chemicals, and cosmetics. As an economist's story put it, Fuji Film diversified more successfully. Film is a bit like skin, both contain collagen. Just as photos fade because of oxidation, cosmetics firms would like you to think that skin is preserved with antioxidants. In Fuji Film's library of two hundred thousand chemical compounds, some four thousand are related to antioxidants. So the company launched a line of cosmetics called Astalift, which is sold in Asia and is being launched in Europe this year.
8:05 Speaker 00 That is, in the year twenty twelve. So, yes, Kodak is now attempting a narrower, later version of that strategy. The only challenge is that pharma manufacturing is crowded and unforgiving. Margins could be thin, quality failures can kill reputations, and Kodak enters as a small fish among the sharks. And to really move the needle, it will have to push into higher value, tightly regulated products where reliability counts as much as price. But whether this reinvention works could decide if Kodak Moments remains a nostalgic relic or a surprising corporate comeback. Thank you for listening to today's episode. And if you want to share your feedback or suggestions, do drop us an email to hi@friendshots.in. Until next time.
Previous Can India become the world’s BPO for semiconductors? Next Can China’s stock market ever deliver like India’s? Page updated November 11, 2026 · transcript and summary are machine-generated